Elanco Animal Health Reports Strong Q1 2026 Performance with Revenue Growth and Product Success
Elanco Animal Health delivered strong financial results in the first quarter of 2026, including a 10% organic constant currency revenue growth driven by price and volume gains. Key products like Zenrelia reached blockbuster status while new product launches contributed to market share expansion.
Tickers: $COST $DG $ELAN $NVDA
Topics: animal health guidance update product performance revenue growth